JP2021535727A5 - - Google Patents
Info
- Publication number
- JP2021535727A5 JP2021535727A5 JP2020556258A JP2020556258A JP2021535727A5 JP 2021535727 A5 JP2021535727 A5 JP 2021535727A5 JP 2020556258 A JP2020556258 A JP 2020556258A JP 2020556258 A JP2020556258 A JP 2020556258A JP 2021535727 A5 JP2021535727 A5 JP 2021535727A5
- Authority
- JP
- Japan
- Prior art keywords
- fusion protein
- recombinant fusion
- recombinant
- nrg
- protein according
- Prior art date
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023097663A JP7631420B2 (ja) | 2018-04-11 | 2023-06-14 | ヒトニューレグリン－１（ｎｒｇ－１）組換え型融合タンパク質組成物及びその使用方法 |
| JP2025017265A JP2025072502A (ja) | 2018-04-11 | 2025-02-05 | ヒトニューレグリン－１（ｎｒｇ－１）組換え型融合タンパク質組成物及びその使用方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862656246P | 2018-04-11 | 2018-04-11 | |
| US62/656,246 | 2018-04-11 | ||
| PCT/US2019/026889 WO2019200033A1 (en) | 2018-04-11 | 2019-04-11 | Human neuregulin-1 (nrg-1) recombinant fusion protein compositions and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023097663A Division JP7631420B2 (ja) | 2018-04-11 | 2023-06-14 | ヒトニューレグリン－１（ｎｒｇ－１）組換え型融合タンパク質組成物及びその使用方法 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021535727A JP2021535727A (ja) | 2021-12-23 |
| JPWO2019200033A5 JPWO2019200033A5 (https=) | 2022-04-19 |
| JP2021535727A5 true JP2021535727A5 (https=) | 2022-04-19 |
| JP7575272B2 JP7575272B2 (ja) | 2024-10-29 |
Family
ID=66484143
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020556258A Active JP7575272B2 (ja) | 2018-04-11 | 2019-04-11 | ヒトニューレグリン－１（ｎｒｇ－１）組換え型融合タンパク質組成物及びその使用方法 |
| JP2023097663A Active JP7631420B2 (ja) | 2018-04-11 | 2023-06-14 | ヒトニューレグリン－１（ｎｒｇ－１）組換え型融合タンパク質組成物及びその使用方法 |
| JP2025017265A Pending JP2025072502A (ja) | 2018-04-11 | 2025-02-05 | ヒトニューレグリン－１（ｎｒｇ－１）組換え型融合タンパク質組成物及びその使用方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023097663A Active JP7631420B2 (ja) | 2018-04-11 | 2023-06-14 | ヒトニューレグリン－１（ｎｒｇ－１）組換え型融合タンパク質組成物及びその使用方法 |
| JP2025017265A Pending JP2025072502A (ja) | 2018-04-11 | 2025-02-05 | ヒトニューレグリン－１（ｎｒｇ－１）組換え型融合タンパク質組成物及びその使用方法 |
Country Status (25)
| Country | Link |
|---|---|
| US (3) | US11046741B2 (https=) |
| EP (2) | EP3774859B1 (https=) |
| JP (3) | JP7575272B2 (https=) |
| KR (1) | KR102949228B1 (https=) |
| CN (2) | CN113166218B (https=) |
| AU (2) | AU2019252262B2 (https=) |
| BR (1) | BR112020020646A2 (https=) |
| CA (1) | CA3096420A1 (https=) |
| CL (1) | CL2020002621A1 (https=) |
| CO (1) | CO2020012621A2 (https=) |
| DK (1) | DK3774859T3 (https=) |
| EA (1) | EA202092458A1 (https=) |
| ES (1) | ES2980163T3 (https=) |
| FI (1) | FI3774859T3 (https=) |
| HU (1) | HUE066892T2 (https=) |
| IL (2) | IL322374A (https=) |
| MX (2) | MX2020010740A (https=) |
| MY (1) | MY204230A (https=) |
| PE (1) | PE20210111A1 (https=) |
| PH (1) | PH12020551648A1 (https=) |
| PL (1) | PL3774859T3 (https=) |
| PT (1) | PT3774859T (https=) |
| SG (1) | SG11202009831UA (https=) |
| TW (2) | TWI888027B (https=) |
| WO (1) | WO2019200033A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20210111A1 (es) | 2018-04-11 | 2021-01-19 | Salubris Biotherapeutics Inc | Composiciones de proteina de fusion recombinante neuregulina-1 (nrg-1) humana y metodos para su uso |
| AR121035A1 (es) | 2019-04-01 | 2022-04-13 | Lilly Co Eli | Compuestos de neuregulina-4 y métodos de uso |
| AU2020348436A1 (en) * | 2019-09-16 | 2022-04-07 | Zensun (Shanghai) Science & Technology, Co., Ltd. | Recombinant human neuregulin derivatives and use thereof |
| CN114420310B (zh) * | 2022-01-18 | 2024-11-12 | 河南大学 | 基于图转换网络的药物ATC Code预测方法 |
| WO2023178086A1 (en) * | 2022-03-15 | 2023-09-21 | Salubris Biotherapeutics, Inc. | Methods of treating fibrosis and arrhythmia with a neuregulin-1 fusion protein |
| CN116832040B (zh) * | 2023-06-12 | 2026-01-13 | 北京市心肺血管疾病研究所 | 细胞周期蛋白依赖性激酶抑制剂在治疗射血分数保留型心力衰竭中的应用 |
| WO2025122581A1 (en) * | 2023-12-08 | 2025-06-12 | The Trustees Of Indiana University | Compositions comprising neuregulin and methods of using the same to treat or prevent neurotrophic keratitis |
| WO2025245112A1 (en) | 2024-05-21 | 2025-11-27 | Salubris Biotherapeutics, Inc. | Neuregulin-1/anti-her3 antibody fusion protein for use in the treatment of heart failure |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5204244A (en) | 1987-10-27 | 1993-04-20 | Oncogen | Production of chimeric antibodies by homologous recombination |
| US5202238A (en) | 1987-10-27 | 1993-04-13 | Oncogen | Production of chimeric antibodies by homologous recombination |
| US5464764A (en) | 1989-08-22 | 1995-11-07 | University Of Utah Research Foundation | Positive-negative selection methods and vectors |
| US5716930A (en) | 1991-04-10 | 1998-02-10 | Ludwig Institute For Cancer Research | Glial growth factors |
| US5530109A (en) | 1991-04-10 | 1996-06-25 | Ludwig Institute For Cancer Research | DNA encoding glial mitogenic factors |
| IL101943A0 (en) * | 1991-05-24 | 1992-12-30 | Genentech Inc | Structure,production and use of heregulin |
| US5834229A (en) | 1991-05-24 | 1998-11-10 | Genentech, Inc. | Nucleic acids vectors and host cells encoding and expressing heregulin 2-α |
| US5541110A (en) | 1994-05-17 | 1996-07-30 | Bristol-Myers Squibb | Cloning and expression of a gene encoding bryodin 1 from Bryonia dioica |
| US5912326A (en) | 1995-09-08 | 1999-06-15 | President And Fellows Of Harvard College | Cerebellum-derived growth factors |
| AUPP785098A0 (en) * | 1998-12-21 | 1999-01-21 | Victor Chang Cardiac Research Institute, The | Treatment of heart disease |
| US6635249B1 (en) | 1999-04-23 | 2003-10-21 | Cenes Pharmaceuticals, Inc. | Methods for treating congestive heart failure |
| WO2003099320A1 (en) * | 2002-05-24 | 2003-12-04 | Zensun (Shanghai) Sci-Tech.Ltd | Neuregulin based methods and compositions for treating viral myocarditis and dilated cardiomyopathy |
| EP1824879B1 (en) | 2004-07-09 | 2014-10-29 | Wayne State University | HYBRID PROTEINS WITH ErbB4 EXTRACELLULAR DOMAIN AND NEUREGULIN HEPARIN-BINDING DOMAIN FOR TARGETING |
| US8053569B2 (en) * | 2005-10-07 | 2011-11-08 | Armagen Technologies, Inc. | Nucleic acids encoding and methods of producing fusion proteins |
| US20070213264A1 (en) | 2005-12-02 | 2007-09-13 | Mingdong Zhou | Neuregulin variants and methods of screening and using thereof |
| BRPI0818033A2 (pt) | 2007-10-16 | 2015-03-24 | Symphogen As | Composições compreendendo multímeros otimizados de her1 e her3 e métodos para usos dos mesmos |
| WO2009114110A1 (en) * | 2008-03-08 | 2009-09-17 | Immungene, Inc. | Engineered fusion molecules immunotherapy in cancer and inflammatory diseases |
| WO2010006059A1 (en) * | 2008-07-08 | 2010-01-14 | Abbott Laboratories | Prostaglandin e2 binding proteins and uses thereof |
| JP5743898B2 (ja) | 2008-11-28 | 2015-07-01 | ゼンサン （シャンハイ） サイエンス アンド テクノロジー リミテッド | ニューレグリンペプチド及びその使用 |
| JP2013507378A (ja) * | 2009-10-09 | 2013-03-04 | メルク・シャープ・エンド・ドーム・コーポレイション | 抗ｈｅｒ３抗体の製造、特徴づけ及びその用途 |
| CN102139095A (zh) | 2010-01-29 | 2011-08-03 | 上海泽生科技开发有限公司 | 神经调节蛋白用于预防、治疗或延迟心脏缺血再灌注损伤的方法和组合物 |
| US9029328B2 (en) | 2010-03-24 | 2015-05-12 | The Brigham And Women's Hospital, Inc. | Methods for cardioprotection and cardioregeneration with dimers of EGF family ligands |
| WO2013053076A1 (en) | 2011-10-10 | 2013-04-18 | Zensun （Shanghai）Science & Technology Limited | Compositions and methods for treating heart failure |
| CA2929386C (en) * | 2013-11-07 | 2023-01-03 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Neuregulin allosteric anti-her3 antibody |
| CN104758922A (zh) | 2014-01-03 | 2015-07-08 | 上海泽生科技开发有限公司 | 纽兰格林制剂的配方 |
| KR102399277B1 (ko) * | 2014-04-10 | 2022-05-18 | 다이이찌 산쿄 가부시키가이샤 | 항her3 항체-약물 콘주게이트 |
| CA2959716A1 (en) * | 2014-09-08 | 2016-03-17 | Yeda Research And Development Co. Ltd. | Anti-her3 antibodies and uses of same |
| CN105561298A (zh) * | 2014-10-17 | 2016-05-11 | 上海泽生科技开发有限公司 | 神经调节蛋白用于预防、治疗或延迟射血分数保留的心力衰竭的方法和组合物 |
| RU2767329C2 (ru) | 2016-02-06 | 2022-03-17 | Эпимаб Биотерапьютикс, Инк. | Иммуноглобулин с тандемными fab-фрагментами и варианты его применения |
| CN110167968B (zh) | 2016-09-15 | 2023-11-28 | 斯图加特大学 | 针对her3的抗原结合蛋白 |
| PE20210111A1 (es) | 2018-04-11 | 2021-01-19 | Salubris Biotherapeutics Inc | Composiciones de proteina de fusion recombinante neuregulina-1 (nrg-1) humana y metodos para su uso |
-
2019
- 2019-04-11 PE PE2020001553A patent/PE20210111A1/es unknown
- 2019-04-11 EP EP19723548.4A patent/EP3774859B1/en active Active
- 2019-04-11 EA EA202092458A patent/EA202092458A1/ru unknown
- 2019-04-11 FI FIEP19723548.4T patent/FI3774859T3/fi active
- 2019-04-11 SG SG11202009831UA patent/SG11202009831UA/en unknown
- 2019-04-11 WO PCT/US2019/026889 patent/WO2019200033A1/en not_active Ceased
- 2019-04-11 HU HUE19723548A patent/HUE066892T2/hu unknown
- 2019-04-11 CA CA3096420A patent/CA3096420A1/en active Pending
- 2019-04-11 AU AU2019252262A patent/AU2019252262B2/en active Active
- 2019-04-11 KR KR1020207032449A patent/KR102949228B1/ko active Active
- 2019-04-11 MX MX2020010740A patent/MX2020010740A/es unknown
- 2019-04-11 US US16/381,206 patent/US11046741B2/en active Active
- 2019-04-11 IL IL322374A patent/IL322374A/en unknown
- 2019-04-11 CN CN201980025049.3A patent/CN113166218B/zh active Active
- 2019-04-11 TW TW113107264A patent/TWI888027B/zh active
- 2019-04-11 MY MYPI2020005322A patent/MY204230A/en unknown
- 2019-04-11 PT PT197235484T patent/PT3774859T/pt unknown
- 2019-04-11 JP JP2020556258A patent/JP7575272B2/ja active Active
- 2019-04-11 CN CN202411003345.2A patent/CN118909141A/zh active Pending
- 2019-04-11 IL IL277790A patent/IL277790B2/en unknown
- 2019-04-11 TW TW108112630A patent/TWI834654B/zh active
- 2019-04-11 PL PL19723548.4T patent/PL3774859T3/pl unknown
- 2019-04-11 EP EP24161673.9A patent/EP4361177A3/en active Pending
- 2019-04-11 ES ES19723548T patent/ES2980163T3/es active Active
- 2019-04-11 DK DK19723548.4T patent/DK3774859T3/da active
- 2019-04-11 BR BR112020020646-6A patent/BR112020020646A2/pt unknown
-
2020
- 2020-10-02 PH PH12020551648A patent/PH12020551648A1/en unknown
- 2020-10-09 CL CL2020002621A patent/CL2020002621A1/es unknown
- 2020-10-09 MX MX2025002112A patent/MX2025002112A/es unknown
- 2020-10-21 CO CONC2020/0012621A patent/CO2020012621A2/es unknown
-
2021
- 2021-05-21 US US17/327,494 patent/US11718652B2/en active Active
-
2023
- 2023-06-13 US US18/333,797 patent/US20230322877A1/en active Pending
- 2023-06-14 JP JP2023097663A patent/JP7631420B2/ja active Active
- 2023-12-20 AU AU2023285793A patent/AU2023285793B2/en active Active
-
2025
- 2025-02-05 JP JP2025017265A patent/JP2025072502A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021535727A5 (https=) | ||
| FI3774859T3 (fi) | Ihmisen neureguliini-1:n (nrg-1) rekombinanttifuusioproteiinikoostumukset ja niiden käyttömenetelmät | |
| JP7358365B2 (ja) | がんを治療するための、化学療法剤と併用した多量体抗ｄｒ５結合分子の使用 | |
| JP7376490B2 (ja) | ＩｇＭ血清半減期に影響を及ぼすＩｇＭ Ｆｃ及びＪ鎖の変異 | |
| AU2020201323B2 (en) | Tumor necrosis factor (tnf) superfamily receptor binding molecules and uses thereof | |
| CN100424175C (zh) | ErbB-3 用于肿瘤治疗的方法和组合物 | |
| CN107074928B (zh) | 新型猫促红细胞生成素受体激动剂 | |
| ES2752248T3 (es) | Heterodímero proteínico y uso del mismo | |
| JP4398644B2 (ja) | ＥｒｂＢ界面ペプチド擬態およびその使用方法 | |
| JP2022511804A (ja) | Ｐｄ－ｌ１とｖｅｇｆを標的化する組換えタンパク質 | |
| CN107446045A (zh) | 一种抗her2的抗体、其药物组合物及用途 | |
| AU2016263808A1 (en) | Trispecific binding proteins and methods of use | |
| JP2009525762A (ja) | 二価性ＥｒｂＢリガンド結合分子ならびにその調製および使用のための方法 | |
| US9731007B2 (en) | Tumour necrosis factor receptor fusion proteins and methods of using the same | |
| US20230192887A1 (en) | Engineered anti-her2 bispecific proteins | |
| KR20230010221A (ko) | 암 치료를 위한 암 요법과 병용된 다량체 항-dr5 결합 분자의 용도 | |
| CN105229025A (zh) | 位点特异性胰岛素缀合物 | |
| JPWO2019200033A5 (https=) | ||
| JP2005500052A5 (https=) | ||
| WO2014166029A1 (zh) | 针对表皮生长因子受体的抗体 | |
| KR20150097304A (ko) | 항 EGFR DARPin을 포함하는 EGFR/HER2 이중 특이 항체 | |
| US20090214576A1 (en) | Tyrosine kinase inhibitor compositions and methods for manufacturing and using them in the treatment of disease | |
| JP6887944B2 (ja) | 抗ｆｇｆｒ２抗体と他剤を含む組成物 | |
| WO1991008754A1 (fr) | Application medicinale de m-csf | |
| WO2022242757A1 (zh) | 抗pd-1抗体的应用 |